Oncolytic Virotherapy for human malignant mesothelioma: recent advances

Abstract : Cancer virotherapy is an attractive alternative to conventional treatments because it offers a wide range of antitumor effects due to 1) the diversity of the oncolytic viruses that are now available and 2) their multifaceted activities against both tumor cells and tumor vessels, in addition to their ability to induce antitumor immune responses. In this review, we summarize preclinical and clinical data regarding the targeting of malignant mesothelioma (MM) by oncolytic viruses. We also discuss the potential of other oncolytic viruses that have already shown antitumor effects against several malignancies in advanced clinical trials but are yet to be tested against MM cells. Finally, we review how the activation of the immune system and combinations with other types of anticancer treatments could support the development of oncolytic virotherapy for the treatment of MM.
Type de document :
Article dans une revue
Oncolytic Virotherapy, DovePress, 2015, 〈10.2147/OV.S66091〉
Liste complète des métadonnées

Littérature citée [72 références]  Voir  Masquer  Télécharger

Contributeur : Elizabeth Bernardo <>
Soumis le : mercredi 9 mars 2016 - 09:53:33
Dernière modification le : jeudi 20 septembre 2018 - 17:02:01
Document(s) archivé(s) le : dimanche 13 novembre 2016 - 12:07:53


Fichiers éditeurs autorisés sur une archive ouverte




Nicolas Boisgerault, Carole Achard, Laurent Cellerin, Frédéric Tangy, Marc Grégoire, et al.. Oncolytic Virotherapy for human malignant mesothelioma: recent advances. Oncolytic Virotherapy, DovePress, 2015, 〈10.2147/OV.S66091〉. 〈inserm-01285355〉



Consultations de la notice


Téléchargements de fichiers